发明公开
EP3082814A1 USE OF LAQUINIMOD TO DELAY HUNTINGTON'S DISEASE PROGRESSION
审中-公开
VERWENDUNG VON LAQUINIMOD ZURVERZÖGERUNGDES FORTSCHRITTS DER HUNTINGTON-KRANKHEIT
- 专利标题： USE OF LAQUINIMOD TO DELAY HUNTINGTON'S DISEASE PROGRESSION
- 专利标题（中）： VERWENDUNG VON LAQUINIMOD ZURVERZÖGERUNGDES FORTSCHRITTS DER HUNTINGTON-KRANKHEIT
-
申请号： EP14871229.2申请日： 2014-12-18
-
公开(公告)号： EP3082814A1公开(公告)日： 2016-10-26
- 发明人: HAGAI, Esther, Lukasiewicz , MELAMED-GAL, Sigal , EYAL, Eli , WICKENBERG, Anna
- 申请人： Teva Pharmaceutical Industries Ltd.
- 申请人地址： 5 Basel Street P.O. Box 3190 49131 Petah Tiqva IL
- 专利权人： Teva Pharmaceutical Industries Ltd.
- 当前专利权人： Teva Pharmaceutical Industries Ltd.
- 当前专利权人地址： 5 Basel Street P.O. Box 3190 49131 Petah Tiqva IL
- 代理机构： D Young & Co LLP
- 优先权： US201361919604P 20131220
- 国际公布： WO2015095548 20150625
- 主分类号： A61K31/4704
- IPC分类号： A61K31/4704 ; A61P25/00
摘要：
The subject invention provides methods of treating or delaying disease progression in a subject afflicted with Huntington's disease (HD) comprising administering to the subject 0.5-1.5 mg/day laquinimod. The subject invention also provides packages, therapeutic packages and pharmaceutical compositions, comprising one or more unit doses of 0.5-1.5 mg laquinimod for treating or delaying disease progression in a subject afflicted with HD. Also disclosed is use of laquinimod in the manufacture of a medicament comprising one or more unit doses of 0.5-1.5 mg laquinimod for use in treating or delaying disease progression in a subject afflicted HD.
信息查询
IPC分类:
